Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3
| VXRT Stock | USD 0.79 0.02 2.60% |
Slightly above 56% of all Vaxart's private investors are looking to take a long position. The analysis of the overall investor sentiment regarding Vaxart Inc suggests that some traders are interested. Vaxart's investing sentiment can be driven by a variety of factors including economic data, Vaxart's earnings reports, geopolitical events, and overall market trends.
Vaxart |
Filed transaction by Vaxart Inc Officer Chief Financial Officer. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Vaxart Fundamental Analysis
We analyze Vaxart's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vaxart using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vaxart based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Vaxart is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Vaxart Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Vaxart stock to make a market-neutral strategy. Peer analysis of Vaxart could also be used in its relative valuation, which is a method of valuing Vaxart by comparing valuation metrics with similar companies.
Peers
Vaxart Related Equities
| OCGN | Ocugen | 2.63 | ||||
| IBIO | Ibio | 1.99 | ||||
| NVAX | Novavax | 3.46 | ||||
| CODX | Co Diagnostics | 4.76 | ||||
| INO | Inovio Pharmaceuticals | 4.80 |
Additional Tools for Vaxart Stock Analysis
When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.